CSC
PCRX icon

Caldwell Sutter Capital’s Pacira BioSciences PCRX Stock Holding History

Caldwell Sutter Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-149
Closed -$3.84K – 899
2025
Q3 		$3.84K Buy
+149
New +$3.66K ﹤0.01% 664

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Caldwell Sutter Capital's PCRX Position: Q4 2025 in Review

Caldwell Sutter Capital sold out of Pacira BioSciences (PCRX) in Q4 2025, closing a stake of 149 shares — an estimated $3.84K sold.

Caldwell Sutter Capital first reported a position in PCRX in Q3 2025 and held it in 1 quarter. The position peaked at $3.84K in Q3 2025. 260 funds tracked by Wall St. Rank hold PCRX as of Q4 2025.

  • Caldwell Sutter Capital reported no remaining Pacira BioSciences position as of Q4 2025 after selling out during the quarter.
  • Caldwell Sutter Capital sold 149 Pacira BioSciences shares in Q4 2025, an estimated $3.84K.
  • Caldwell Sutter Capital first reported a position in Pacira BioSciences in Q3 2025 and held it in 1 quarter.
  • Caldwell Sutter Capital's Pacira BioSciences position peaked at $3.84K in Q3 2025.
  • 260 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2025.

Based on Caldwell Sutter Capital's 13F filing for Q4 2025, filed 30 Jan 2026.